Telix Pharmaceuticals Under Investigation for Securities Fraud and Misconduct.

Pomerantz LLP is investigating claims against Telix Pharmaceuticals Limited (NASDAQ: TLX) for potential securities fraud or unlawful business practices. The investigation follows Telix's disclosure of a subpoena from the U.S. Securities and Exchange Commission related to the company's disclosures on prostate cancer therapeutic candidates. As a result, Telix's American Depositary Receipt price fell 10.44% to close at $14.58 per ADR on July 23, 2025.

Pomerantz LLP has initiated an investigation into potential securities fraud and unlawful business practices involving Telix Pharmaceuticals Limited (NASDAQ: TLX). The investigation follows the company's disclosure of a subpoena from the U.S. Securities and Exchange Commission (SEC) on July 22, 2025, seeking documents and information related to the development of Telix's prostate cancer therapeutic candidates [1].

On July 23, 2025, Telix's American Depositary Receipt (ADR) price fell by 10.44%, closing at $14.58 per ADR [2]. The investigation by Pomerantz LLP aims to determine whether Telix and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices [3].

Investors affected by this situation are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, to discuss potential involvement in the class action [3].

References:
[1] https://www.globenewswire.com/news-release/2025/08/08/3130343/32716/en/Telix-Pharmaceuticals-Limited-TLX-Shares-Fall-Amid-SEC-Subpoena-Hagens-Berman.html
[2] https://www.ainvest.com/news/telix-pharmaceuticals-investigation-potential-securities-fraud-2508/
[3] https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-telix-pharmaceuticals-limited--tlx-302521589.html